$6.85
1.03% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Fulcrum Therapeutics Inc Stock price

$6.85
+1.06 18.31% 1M
+2.89 72.98% 6M
+2.15 45.74% YTD
-0.95 12.18% 1Y
-10.20 59.82% 5Y
-6.65 49.26% 10Y
-6.65 49.26% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.07 1.03%
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Key metrics

Market capitalization $369.76m
Enterprise Value $143.16m
EV/FCF (TTM) EV/FCF 18.94
P/B ratio (TTM) P/B ratio 1.62
Free Cash Flow (TTM) Free Cash Flow $7.56m
Cash position $226.60m
P/E forward negative
Short interest 15.21%

Is Fulcrum Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Fulcrum Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Fulcrum Therapeutics Inc forecast:

4x Buy
57%
2x Hold
29%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Fulcrum Therapeutics Inc forecast:

Buy
57%
Hold
29%
Sell
14%

Financial data from Fulcrum Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
80 80
2,747% 2,747%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
13% 13%
46%
- Research and Development Expense 63 63
12% 12%
79%
-18 -18
83% 83%
-23%
- Depreciation and Amortization 1.59 1.59
27% 27%
2%
EBIT (Operating Income) EBIT -20 -20
82% 82%
-25%
Net Profit -9.73 -9.73
90% 90%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about Fulcrum Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulcrum Therapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the com...
Neutral
GlobeNewsWire
16 days ago
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Associatio...
Neutral
GlobeNewsWire
16 days ago
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in...
More Fulcrum Therapeutics Inc News

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Sapir
Employees 45
Founded 2015
Website www.fulcrumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today